Seventy-two adults already using automated insulin delivery joined the trial [1]. The question of whether a GLP-1 can replace insulin is distinct from adding one. Both trial groups continued insulin.
What the trial measured
Adults with type 1 diabetes and obesity received weekly semaglutide up to 1 mg or placebo for 26 weeks [1]. The main outcome required meeting three targets. Glucose had to stay between 70 and 180 mg/dL more than 70% of the time. Time below 70 mg/dL had to be under 4%. Participants also had to lose at least 5% of their weight.
Thirty-six percent of the semaglutide group met all three targets. None in the placebo group did. The difference was 36 percentage points, with a 95% confidence interval of 20.6 to 52.2. Time in range improved by 8.8 percentage points more with semaglutide. The difference in average weight change was 8.8 kg in favor of semaglutide.
What the safety results can tell us
Each group had two severe low blood sugar events. The researchers reported no diabetic ketoacidosis in either group. An earlier crossover trial reported two episodes of ketosis with normal glucose during semaglutide use [2]. Neither episode progressed to ketoacidosis.
Ozempic’s FDA label does not include treatment of type 1 diabetes [3]. The differences between semaglutide brands matter when checking a product’s approved uses. This trial cannot establish safety over longer periods or in people using insulin injections alone.